Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

HTS discovery of PARP1-HPF1 complex inhibitors in cancer

SLAS DISCOVERY(2023)10.1016/j.slasd.2023.10.003Source: DataRank Database

HTS discovery of PARP1-HPF1 complex inhibitors in cancer is a research paper published in SLAS DISCOVERY (2023). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 0.80)OA: goldTopics (56)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Rida Noor,Qiong Zhou ORCID,Hector Esquer ORCID,Rita Sala ORCID,Petra Stojanovic ORCID

Live enrichment

PubMed:37844763 OpenAlex:https://openalex.org/W4387640800

National Institutes of Health

Grant: 3P30CA046934-20S2

Cancer Center Support Grant

National Institutes of Health

Grant: 5R01CA251361-05

The Development of First-in-Class Inhibitors of Oncogenic CHD1L for the Treatment of Colorectal Cancer.

National Institutes of Health

Grant: 5R01CA218255-09

Structure and Mechanism of Chromatin-Bound PARP1

NCI NIH HHS

Grant: P30 CA008748

NCI NIH HHS

Grant: P30 CA046934

NCI NIH HHS

Grant: R01 CA218255

NCI NIH HHS

Grant: R01 CA251361

FWCI

0.80

Citation Percentile

0.7%

Citation Trend

2023

2024

2025

goldLicense: cc-by

journalhttp://slas-discovery.org/article/S2472555223000692/pdf

publisherhttp://slas-discovery.org/article/S2472555223000692/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2472555223000692?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2472555223000692?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.slasd.2023.10.003

Fields of Study

PARP inhibition in cancer therapyDNA Repair MechanismsAdvancements in Semiconductor Devices and Circuit Design03 medical and health sciences0302 clinical medicineHumansCatalytic DomainHistonesNeoplasmsNuclear ProteinsPoly (ADP-Ribose) Polymerase-1Poly ADP RibosylationPoly(ADP-ribose) Polymerase InhibitorsCarrier Proteins

MeSH Terms

Poly(ADP-ribose) Polymerase InhibitorsPoly (ADP-Ribose) Polymerase-1Poly ADP RibosylationCarrier ProteinsHistonesHumansNeoplasmsNuclear ProteinsCatalytic Domain

Keywords

PARP1DNA Damage RepairComputational biologyHistoneSynthetic lethalityDNA damageCancerPoly ADP ribose polymeraseDrug discoveryBiologyCancer researchComputer scienceDNA repairBioinformaticsDNAGeneticsPolymeraseHistonesPoly ADP RibosylationCatalytic DomainNeoplasmsPoly (ADP-Ribose) Polymerase-1HumansNuclear ProteinsPoly(ADP-ribose) Polymerase InhibitorsCarrier ProteinsArticleAssay developmentDNA damage responseHPF1HTSPARP1/2Robotic automation

Sustainable Development Goals

SDG 0: Good health and well-being